Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk.
This article dissects considerations for how to reduce risk, manage costs and optimize performance while maintaining control of your asset.
